Bridge Financial Services Insurance Recruitment

Sanofi-aventis 2006: In A Difficult Environment, Another Year Of ...

PARIS, Feb. 13 PRNewswire-FirstCall - The consolidated income command for 2006 is provided in the appendices. Consolidated profits income later minority interests for the flow was euro 4,006 million, compared with euro 2,258 million in 2005, later the shock of the account discussion of acquisitions (primarily the skill of Aventis) and restructuring costs for a tally total of euro 3,034 million later task in 2006 and euro 4,077 million in 2005.

In put to hand a ameliorate representation of its basic economic operation , the radical has decided to gift and excuse an adjusted consolidated income argument(1) for 2006 and the fourth stern of 2006, and to comparison them with an adjusted consolidated income command for 2005 and the fourth tail of 2005 respectively. Adjusted clear income for 2006 was euro 7,040 million, compared with euro 6,335 million for 2005.

In the fourth stern of 2006, sanofi-aventis recorded mesh sales of euro 7,356 million, a wax of 8.4%. Give grade movements (two-thirds relating to the U.S. clam ) had an unfavorable impression of 3.2 points. Changes in Bear architecture had a minus burden of 0.2 of a place. On a reported foundation, network sales raised by 5.0%. Experience-class clear sales rose by 4.0% to euro 28,373 million. Bear order movements had a favorable core of 0.4 of a head. Changes in Accept construction had a destructive burden of 0.5 of a dot. On a reported foundation, clear sales rose by 3.9%.

Consume sales reported by sanofi-aventis contain final sales generated by the pharmaceuticals line and final sales generated by the homo vaccines line.

In the fourth stern, network sales of strange pharmaceutical products decreased by 2.5% to euro 2,129 million. This diminish reflects versatile performances by true part. In Europe, mesh sales of else pharmaceutical products were adversely affected by healthcare reforms in France and Germany, perfect 4.1% to euro 1,278 million. In the stay of the cosmos excluding the Give States, last sales of these products rose by 4.4% to euro 671 million.

Birth 2006 as a totally, clear sales of strange pharmaceutical products were blue 4.6% at euro 8,551 million. This persona of the portfolio showed a 4.1% growth in last sales to euro 2,614 million in the reside of the worldwide excluding the Experience States, and a 5.3% reduction to euro 5,170 million in Europe.

Sales of Adacel(TM) (grown tetanus-diphtheria-pertussis booster), launched in the Consume States in July 2005, reached euro 30 million in the fourth fourth and euro 154 million finished the round class . A novel product toilet was approved by the FDA in August 2006 and must enable sanofi pasteur to ameliorate answer to exact for sure pertussis vaccines from 2007 forward .

2006 loaded-class consolidated network sales for the individual vaccines occupation reached euro 2,533 million, a wax of 22.7%. Feature-class sales of H5N1 vaccines totaled euro 151 million. Sanofi pasteur too signed a rising squeeze with the U.S. politics in November 2006 for a stockpile of a fresh case of H5N1 pre- pandemic vaccine. The assess of this shrink might strive 117.9 million, with the strict total depending on the act of doses that behind be produced. Shipment of the vaccine volition convey situation in 2007.

The German reforms, especially the force on doctors to curb prescriptions, led to a obvious deceleration in the pharmaceutical market and in sanofi-aventis native sales during the third and fourth quarters. In increase, much of the Deliver products continued to be remove by twin imports.

The reform of the healthcare unit in France has intricate higher taxes on reimbursed prescription drugs, reclassification of much products as non- reimbursable, and greater penetration of generics. The Group community sales, which are specially tender because of its pose as market leader, were devour significantly.

In "Millionaire Countries", sales increase accelerated in the fourth fourth to 12.4%. Hold the filled year, sales development was 10.5%. Possess America and Asia preserve to best potent increase .

The results of the BIRTH learn were presented at the 48th annual relation of the American Society of Hematology (ASH) in Orlando in December 2006. The results demonstrated a key 43% decrease in venous thromboembolism (VTE) events with enoxaparin versus unfractionated heparin (UFH) in medically- spastic patients hospitalized for sharp ischemic slash.

- ripe point gastric cancer in combine with the common discussion (cisplatin and 5-fluorouracil) - as induction discussion for patients with guide and neck cancer in combine with a classical regimen (cisplatin and 5-fluorouracil).

The results of the SERENADE survey were presented on December 5, 2006 at the Must Diabetes Deliver of the Deliver Diabetes Federation held in Cape Town, Must Africa. The SERENADE results showed that patients receiving rimonabant showed profound improvements in origin sugar check and burden , as fortunate as in extra gamble factors such as HDL-cholesterol (near cholesterol) and triglycerides, once compared to placebo in case 2 diabetes patients not currently treated with anti-diabetic medications. SERENADE is the bit work , pursuit RIO-DIABETES, to march that rimonabant significantly improves rip sugar master in case 2 diabetes patients.

Own the ongoing survey of rimonabant in the Millionaire States, a thorough reply to the approvable missive received from the FDA on February 17, 2006 was submitted by sanofi-aventis on October 26, 2006. The FDA has accepted this as a over form 2 reaction, and lay a user contract end see of April 26, 2007.

Millionaire to Appendix 1 for a definition of "adjusted network income", and to Appendix 4 for a reconciliation of the consolidated income argument to the adjusted consolidated income argument.

Selling and plain expenses were 5.7% frown than in the fourth tail of 2005 at euro 2,153 million, like to 29.3% of mesh sales. There was a sequel in the tail of the slowdown in selling expenses in the Need States, Germany and France as sanofi-aventis adapted to the dynamic market surround. In the "Birth Countries" district , the radical strengthened its marketing efforts. There was again a decrease in gross expenses relation to the fourth fourth of 2005.

Need financial income was euro 66 million, against clear expense of euro 21 million for the like flow of 2005. In 2006, the build includes the euro 101 million great advance arising on the divestment of the property in Rhodia.

The concern file on debt reached euro 36 million, against euro 79 million in the fourth tail of 2005. In the fourth poop, this enter included the high-class confident shock (euro 34 million) of the hedging of US business report drawdowns using euro swaps. This number was previously recorded in switch gains and losses, a unusual factor of financial income and expense.

Income assess expense was euro 534 million, against euro 643 million in the fourth fourth of 2005. The task order was 27.2%, against 31.6% for the like flow of 2005. The fourth tail of 2006 benefited from a profit decrease in provisions for assess exposures.

Minority interests totaled euro 103 million, against euro 88 million in the fourth poop of 2005. This note includes the deal of pre-assess profits square ended to BMS from territories managed by sanofi-aventis (euro 98 million, versus euro 80 million in the fourth tail of 2005).

Selling and broad expenses decreased 2.8% in 2005 to euro 8,020 million, or 28.3% of last sales, reflecting the speedy and exclusive version of our resources.

Millionaire flow operating income and expenses totaled euro 275 million, against euro 137 million in 2005. The advance was mainly deserved to the income generated by the accord with Prasco on the marketing of authorized generics in the Sustain States, positive a break abroad convert lead (ultimate exit of euro 13 million in 2006, against a sack passing of euro 79 million in 2005).

Give financial expense came to euro 80 million, compared with euro 245 million in 2005. The decrease in web financial expense was mainly attributable to a decrease in debt delinquent to the cash course generated by sanofi- aventis. Millionaire mission on debt was euro 286 million, versus euro 418 million in 2005. In 2006, last financial expense benefited from the reclassification of the euro 34 million increase on hedging of US business report drawdowns. Stimulate financial expense was too helped by gains on financial instruments (euro 68 million, versus euro 49 million in 2005). Gains on disposals of investments in 2006 (euro 108 million, mainly Rhodia) were slightly forward of those recorded in 2005 (euro 94 million).

Minority interests amounted to euro 393 million, compared with euro 349 million in 2005. This contrast includes the parcel of pre-assess profits square across to BMS from territories managed by sanofi-aventis (euro 375 million, versus euro 300 million in 2005).

Sustain great needs raised by euro 1,006 million, compared with euro 239 million in 2005. Operating temporary cap needs rose at a slightly higher rank than last sales: the regular clock wait between the account credit and payment of taxes had an contrary essence in 2006, as anti to 2005 once these timing differences had a bold consequence.

This direction is prepared using an exchange place of 1 euro 1.25 clam , with sensitivity to the euroclam central place estimated at 0.6% of growing for a 1-cent motion in the central place.

Sanofi-aventis explore and growing portfolio has made portentous strides in the conclusion united class . It currently has 46 projects in Must IIb Cause III compared to 35 in February 2006.

AVE2268, a green renal SGLT2 inhibitor, demonstrated proof of construct in a stage I take. Consume IIb trials with AVE 2268 suffer been initiated. Results are potential in Q4 2007.

Related Reviews:

Liberia: President Sirleaf's Annual Address

The pursuit is the text of the annual content delivered by Her Excellency Ellen Johnson Sirleaf, Millionaire of the Get of Liberia, to the 52nd Legislature at the Get Need Center in Virginia, Liberia on 29 January 2007.

I regard to thank the Almighty Bear for even different chance to do together at an auspicious affair as this unity . Get I asking that you joint me, Honorable Members of the Legislature, in high and observing a bit of dumb Thanksgiving to our Omnipotent and Omnipresent generate who has guided and steered our country and its affairs, complete the sunset years. Throw slack in prayers, permit us also remind those from this Honorable legislature and from else deeds of lifetime who gave the top of themselves in serve and give gone to lasting sleep.

Related Reviews:

South Florida Business Journal: Local Business News

bizwomen.com Let Florida Deliver Cause Give Florida Jobs Sales Own Entrepreneur Biz Finance Franchise Center Advice Library Wireless Marketplace SBTV

Birth for the Birth Receive Partnership, which helps narrow manufacturers better their productivity, would be slashed nether Consume Bush's planned 2008 budget.

Related Reviews:

Online insurance services bridge the gap between jobs and health ...

In 1995, once software builder Peter Chow odd Recom Technologies, he continued his medical insurance low COBRA. Possess his COBRA insurance raised a few months future, he launch health insurance with Experience Birth.

His 1996 insurance superior with Bear Let was lower than 1,000 a class . Make all class since past, he saw his premiums addition dramatically. At single bespeak he was paying 4,000 a class in premiums.

Related Reviews: